The coming months should see the launch of a drug product that uses NanoGuardian's NanoEncryption brand protection technology. The launch, expected from a top-five drugmaker's candidate that is currently in review, will mark the first commercial use of the security technology, says SecuringPharma.
The technology provides unit-level protection against counterfeiting and diversion via three levels of security, as we've reported. The overt, covert and forensic security markings provide authentication and tracing data on capsules, tablets, vial caps, and single-use syringes.
NanoGuardian announced earlier this year that it had struck a licensing deal with Pfizer's Capsugel drug delivery division, enabling Capsugel to offer pre-coded capsule shells to its customers.
- see the article